AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Newron Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference

May 23, 2019

MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)--May 23, 2019--

Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Stefan Weber, CEO, will present at the Jefferies 2019 Healthcare Conference in New York, NY, on Friday, June 7th, 2019 at 1:00 p.m. EDT.

About Newron Pharmaceuticals
Newron (SIX: NWRN) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The company is headquartered in Bresso near Milan, Italy. Xadago® (safinamide) has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland, the US, Australia, Canada, Brazil, and Colombia and is commercialized by Newron’s partner Zambon. US WorldMeds holds the commercialization rights in the USA. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories. In addition to Xadago® for Parkinson’s disease, Newron has a strong pipeline of promising treatments for rare disease patients at various stages of clinical development, including sarizotan for patients with Rett syndrome and ralfinamide for patients with specific rare pain indications. Newron is also developing Evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia. For more information, please visit: www.newron.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190523005372/en/

CONTACT: Newron

Stefan Weber – CEO

+39 02 6103 46 26

pr@newron.comUK/Europe

Julia Phillips / Natalie Garland-Collins, FTI Consulting

+44 20 3727 1000

SCnewron@fticonsulting.comSwitzerland

Martin Meier-Pfister, IRF

+41 43 244 81 40

meier-pfister@irf-reputation.chGermany/Europe

Anne Hennecke, MC Services

+49 211 52925222

anne.hennecke@mc-services.euUSA

Paul Sagan, LaVoieHealthScience

+1 617 374 8800, Ext. 112

psagan@lavoiehealthscience.com

KEYWORD: UNITED STATES EUROPE NORTH AMERICA NEW JERSEY NEW YORK ITALY

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL OTHER HEALTH

SOURCE: Newron Pharmaceuticals S.p.A.

Copyright Business Wire 2019.

PUB: 05/23/2019 08:05 AM/DISC: 05/23/2019 08:05 AM

http://www.businesswire.com/news/home/20190523005372/en

All contents © copyright 2019 The Associated Press.All rights reserved.